Aurobindo Pharma purchases US FDA Compliant facility

New Delhi, July 7 (UNI) Aurobindo Pharma today announced it has acquired a US FDA compliant cGMP facility in Dayton, New Jersey.

The facility, spread over 20 acres of free hold land is located in the heart of Princeton Life Sciences Corridor in the state of New Jersey and is comprised of 100,000 square feet of fully integrated state of the art R&D, formulation manufacturing and distribution facilities with potential for future expansion.

This facility will serve as the Company's US head quarters.

Aurobindo Pharma Chairman Ramprasad Reddy said this purchase reinforces company's commitment to serve US market in an effective manner.

The company has recently concluded zero per cent, foreign currency convertible bonds issue of 200 million dollar.

UNI DKS RP DB2121